Solve Therapeutics vs Grok
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $120M oversubscribed (Nov 2025) with Merck & Co. as new equity investor. $321M total. CloakLink ADC technology reduces hydrophobicity and toxicity. Two Phase 1b solid tumor trials active.
About
Solve Therapeutics develops antibody-drug conjugates (ADCs) using its proprietary CloakLink technology — which reduces the hydrophobicity and systemic toxicity that are the two primary causes of ADC clinical failure. The company raised $120 million in an oversubscribed financing round in November 2025, with Merck & Co. making a direct equity investment (rather than a typical licensing deal), bringing total funding to $321 million. Two ADC programs (SLV-154 and SLV-324) are in active Phase 1b trials in solid tumor patients.
AI assistant by xAI (Elon Musk); Grok 3 topped reasoning benchmarks in Feb 2025; 1M+ paying subscribers in week one; real-time X post access; distributed via X Premium; xAI valued at $24B.
About
Grok is the AI assistant developed by xAI, Elon Musk's AI company founded in 2023, and distributed primarily through X (formerly Twitter). Grok launched in November 2023 as an X Premium perk, with the notable differentiator of real-time access to X posts and a less restricted, more direct conversational style. Grok 3, released in February 2025, achieved top scores on the AIME math reasoning benchmark and ARC-AGI test, briefly positioning xAI as a frontier model lab.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.